PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10093586

Dopamine agonists.

S A Factor
View original source ↗Export metadata ↓

Abstract

Dopamine agonists have been used in the treatment of Parkinson's disease (PD) since the mid 1970s. With the approval of two new agents in 1997, the number available in the United States is up to four; bromocriptine, pergolide, pramipexole, ropinirole. These agents differ in dopamine receptor affinities and chemical structure, which, in turn, may possibly result in differences in efficacy tolerability and safety. Dopamine have historically been used in combination with levodopa in patients with advanced PD, but indicators are now expanding. With is expansion comes increasing controversy. This article reviews dopamine receptor pharmacology and the results of the clinical trials that have used for agonists available in the United States as well as a discussion of three minor agonists.

Explore related subjects

ApomorphineBenzothiazolesBromocriptineDopamine AgonistsHumansIndolesParkinson DiseasePergolidePramipexoleRandomized Controlled Trials as TopicReceptors, DopamineThiazolesTreatment OutcomeJournal ArticleResearch Support, Non-U.S. Gov'tReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S A Factor. 1999. Dopamine agonists.. https://doi.org/10.1016/s0025-7125(05)70112-7

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2000

New treatment for erectile dysfunction.

Numerous advances have been made in our understanding of the evaluation and treatment of erectile dysfunction. Numerous treatment options are currently available. Treatment of this disorder was revolutionized by the introduction of sildenafil, an oral vasoactive agent that has a peripheral mechanism of action, blocking the degradation of cyclic guanosine monophosphate, and thus augmenting the erectogenic effect of sexual stimulation. This agent has proven efficacy in a variety of patient populations, including psychiatric patients. Clinical series suggest that this agent will reverse erectile dysfunction induced by psychoactive agents. Thus, it may play a role in decreasing treatment noncompliance associated with drug-induced sexual dysfunction. Another novel agent that is in development may be of special interest to psychiatrists. Apomorphine is a central dopamine agonist that is believed to act at the level of the paraventricular nucleus of the hypothalamus. As new agents are evolving, our understanding of the neurobiology of sexual function is advancing.

Apomorphine↗